MDGL - Madrigal Pharmaceuticals, Inc.
| Previous Close | 143.52 |
| Open | 142.37 |
| Bid | 139.92 x 1400 |
| Ask | 141.08 x 1800 |
| Day's Range | 139.22 - 142.57 |
| 52 Week Range | 91.56 - 325.98 |
| Volume | 22,948 |
| Avg. Volume | 230,218 |
| Market Cap | 2.168B |
| Beta (3Y Monthly) | 1.48 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.22 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 215.18 |
- Zacks•21 days ago
Intercept (ICPT) Up on Q4 Revenue Beat, NASH Study in Focus
Intercept's (ICPT) Q4 revenues top estimates owing to strong Ocaliva sales, driven by sales force expansion and growth in its foreign geographies.
- Motley Fool•23 days ago
Is Viking Therapeutics a Buy?
Once sky-high stocks of pharmaceutical companies pursing treatments for NASH have gotten a lot cheaper, especially this one.
- Simply Wall St.•23 days ago
All You Need To Know About Madrigal Pharmaceuticals, Inc.’s (NASDAQ:MDGL) Financial Health
Mid-caps stocks, like Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) with a market capitalization of US$2.1b, aren’t the focus of most investors who prefer to direct their investments towards either large-cap or small-capRead More...
- GlobeNewswire•23 days ago
Madrigal Pharmaceuticals Reports 2018 Fourth Quarter and Full Year Financial Results and Highlights
CONSHOHOCKEN, Pa., Feb. 27, 2019 -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its fourth quarter and full year 2018 financial results and highlights:.
- Zacks•last month
Intercept Reports Positive Top-Line Data for NASH, Shares Up
Intercept (ICPT) reports positive top-line results from its pivotal phase III REGENERATE study of OCA in patients with liver fibrosis due to NASH.
- Motley Fool•last month
Better Buy: Intercept Pharmaceuticals vs. Madrigal Pharmaceuticals
Which of these NASH stocks is the better pick right now?
- Zacks•last month
Gilead's (GILD) Late-Stage Study on Liver Disease Drug Fails
Gilead (GILD) suffers a setback as its phase III study on pipeline candidate, selonsertib, in patients with compensated cirrhosis (F4) due to NASH fails to meet goal.
- Motley Fool•2 months ago
Here's Why Viking Therapeutics Slid 32.2% in December
A market scorned for clinical-stage biotech stocks tore a big chunk from this NASH drug developer.
- Motley Fool•2 months ago
Here's Why Viking Therapeutics Skyrocketed 88.4% in 2018
The clinical-stage biotech hopes to tap into what could be a megablockbuster indication.
- Zacks•3 months ago
Intercept (ICPT) Benefits from Ocaliva's Recovery in 2018
Intercept (ICPT) outperforms the broader market in 2018 as lead drug Ocaliva recovers, following the company's efforts to increase awareness about the updated label.
- Insider Monkey•3 months ago
Here is What Hedge Funds Think About Madrigal Pharmaceuticals, Inc. (MDGL)
Looking for stocks with high upside potential? Just follow the big players within the hedge fund industry. Why should you do so? Let’s take a brief look at what statistics have to say about hedge funds’ stock picking abilities to illustrate. The Standard and Poor’s 500 Index returned approximately 5.7% in the 12 months ending October 26 […]
- Motley Fool•3 months ago
3 Beaten-Down Biotech Stocks That Could Bounce Back in 2019
A new year and reasons to remain hopeful for these three biotechs are around the corner.
- Motley Fool•3 months ago
Here's Why Madrigal Pharmaceuticals Fell 39.4% in November
Impressive results from a potential competitor took the shine off this biotech's experimental NASH treatment.
- GlobeNewswire•4 months ago
Report: Exploring Fundamental Drivers Behind CASI Pharmaceuticals, Booking, Enstar Group, Madrigal Pharmaceuticals, Dermira, and Kaiser Aluminum — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Nov. 28, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- GuruFocus.com•4 months ago
Madrigal Pharmaceuticals Inc (MDGL) CEO Paul A Friedman Bought $471,520 of Shares
Madrigal Pharmaceuticals Inc is a company focused on the development of novel compounds for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). Madrigal Pharmaceuticals Inc had annual average EBITDA growth of 43.80% over the past five years. Warning! GuruFocus has detected 4 Warning Signs with T. Click here to check it out.
- Benzinga•4 months ago
Viking Has A More Attractive M&A Valuation Than Madrigal, Raymond James Says In Upgrade
Between Viking's lead asset VK2809 and Madrigal Pharmaceuticals Inc (NASDAQ: MDGL)'s MGL-3196 — both of which are thyroid hormone beta receptor agonists — VK2809 is more potent and tolerable, Seedhouse said in the Monday upgrade note, citing his conversations with investors and physicians. This conviction has increased after the AASLD meeting, the analyst said. Alanine aminotransferase, an enzyme found in liver and kidney cells that is indicative of liver damage, transiently increased from the baseline within the first week of the study and subsequently declined, Seedhouse said.
- Motley Fool•4 months ago
Better NASH Stock: Madrigal Pharmaceuticals, Inc. vs. Viking Therapeutics, Inc.
Positive results for similar candidates recently boosted both of these biotech stocks, but which is the better pick right now?
- American City Business Journals•4 months ago
Madrigal preparing for late-stage testing of experimental NASH treatment
Conshohocken pharmaceutical company Madrigal presented positive midstage testing results of its NASH therapy at medical conference in San Francisco on Monday.
- GlobeNewswire•4 months ago
Phase 2 Results for Madrigal’s MGL-3196 in Non-Alcoholic Steatohepatitis (NASH) Presented during Presidential Plenary Clinical Session of The Liver Meeting® 2018
-- Statistically significantly more NASH resolution in MGL-3196 as compared with placebo in a Phase 2 clinical trial support MGL-3196 as a first- and potentially best-in class.
- Motley Fool•4 months ago
Why Madrigal Pharmaceuticals Stock Slumped in October
Madrigal's stock continued to cool off last month, but another rally could be close at hand.
- GlobeNewswire•4 months ago
Madrigal Pharmaceuticals Reports 2018 Third Quarter Financial Results and Highlights Upcoming Clinical Events
CONSHOHOCKEN, Pa., Nov. 06, 2018 -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its third quarter 2018 financial results and described upcoming clinical.
- Motley Fool•5 months ago
Better Buy: Intercept Pharmaceuticals Inc. vs. Madrigal Pharmaceuticals
Which stock wins in a matchup between these biotechs hoping for success with promising NASH drugs?
Market Realist•5 months agoMadrigal Pharmaceuticals Is Advancing Its NASH Pipeline in 2018
Madrigal Pharmaceuticals (MDGL) is currently studying the thyroid hormone receptor-β (or THR) agonist, MGL-3196, in Phase 2 trials, in nonalcoholic steatohepatitis (or NASH) and familial hypercholesterolemia (or FH)/dyslipidemia indications. The company is studying another investigational THR-β agonist, MGL-3745, in preclinical studies in NASH and syslipidemia/FH indications.
Market Realist•5 months agoMadrigal Pharmaceuticals Stock in the First Half of October
On October 15, Madrigal Pharmaceuticals (MDGL) closed at $189.18, which was 1.28% lower than its previous closing price on October 12. Madrigal Pharmaceuticals stock price had a solid run in the first week of June.
